Facebook
Twitter
LinkedIn
Forward
Timely Management of Moderate-to-Severe Hidradenitis Suppurativa: Addressing Barriers to Care for Patients in Need
Hidradenitis suppurativa (HS), also called acne inversa, is an inflammatory disease characterized by recurring, painful abscesses, and fistulous tracts, and can impact adults and pediatric patients. Symptoms of HS include pain and scarring as well as psychological consequences, such as embarrassment, social isolation, and depression, and is associated with a poor quality of life. Several studies suggest that the prevalence of HS ranges from 0.00033 to 4.1%, although underdiagnosis or improper diagnosis is an issue.
“People living with conditions, such as hidradenitis suppurativa, that are lesser known and have misunderstood symptoms face considerable hardships when seeking diagnosis, treatment and HCPs that fit their needs.” -Olivier Chateau (Co-Founder/CEO, Health Union) |
Immunomodulation is rapidly becoming the cornerstone of therapy for moderate-to-severe HS, with one immunomodulatory agent being the only FDA-approved therapy for this condition to date. As such, clinicians that treat patients with HS would benefit from additional education in several areas pertaining to HS, including expert recommendations for diagnosis and assessing severity, safety and efficacy of emerging therapeutic options, and strategies for implementation of patient-centered treatment to their practice. This 1-hour educational activity, originally presented live at the 21st Annual South Beach Symposium, addresses these gaps through clinical evidence-based discussion and case-based learning led by the foremost experts in treating HS.
Target Audience
This activity is designed for an audience of physicians, nurses, pharmacists, and other allied health providers (nurse practitioners/physician assistants) in medical practices that specialize in dermatology.
Learning Objectives
- Describe evidence-based diagnostic criteria to diagnose HS patients in a timely manner
- Discuss the clinical safety and efficacy data for current and investigational agents for moderate-to-severe HS
- Discuss strategies for early diagnosis of HS and patient-centered treatment selection
- Introductory Remarks
- Addressing Challenges in Identifying HS: How to Avoid Delayed or Missed Diagnosis
- Current Treatments for HS
- Biologics and Small Molecule Inhibitors: Investigational Agents for HS
- Applying the Evidence: Patient Case (in partnership with HS Connect)
- Concluding Remarks/Q&A
Jennifer L. Hsiao, MD
Associate Clinical Professor
University of Southern California
Los Angeles, CA
Barry I. Resnik, MD
Medical Director
Resnik Skin Institute
Aventura, FL
Steven D. Daveluy, MD
Associate Professor
Wayne State University
Dearborn, MI
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and LivDerm. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Credit Designation
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-23-021-H01-P)
This is a knowledge-based activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must attend the activity in person, complete the posttest with 70% or better, and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is $0 fee for this educational activity.
Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corp.
Disclosure
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter | Reported Financial Relationship |
Jennifer L. Hsiao, MD | Consulting Fee (e.g., Advisory Board): Abbvie, UCB, Novartis, Boehringer Ingelheim Speakers' Bureau: Abbvie, UCB, Novartis, Boehringer Ingelheim |
Barry I. Resnik, MD | Nothing to Disclose |
Steven D. Daveluy, MD | Consulting Fee (e.g., Advisory Board): Abbvie, UCB Contracted Research: Abbvie, UCB |
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager | Reported Financial Relationship |
Rhys Williams, MSN, FNP-C, RN | Nothing to disclose |
Lindsay Borvansky | Nothing to disclose |
Andrea Funk | Nothing to disclose |
Liddy Knight | Nothing to disclose |
Ashley Cann | Nothing to disclose |
Lauren Sinclair | Nothing to disclose |
Kelly Pechous | Nothing to disclose |
Deborah Sharkey | Nothing to disclose |
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and LivDerm do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.